Generic injectables are bio-equivalents of their branded counterparts which are not protected by drug patents. They are as safe and effective as the innovator drugs since they have similar active ingredient, dosage, strength, quality, form, etc.

The global Generic Injectables market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Generic Injectables volume and value at global level, regional level and company level. From a global perspective, this report represents overall Generic Injectables market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Generic Injectables in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Generic Injectables manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Pfizer
Sandoz International
Baxter
Fresenius
Mylan
Teva Pharmaceutical
Hikma Pharmaceuticals
Lupin Pharmaceuticals
Sanofi
Biocon

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Large Molecule Injectables (Biosimilars)
Small Molecule Injectables

Segment by Application
Oncology
Infectious Diseases
Cardiology
Diabetes
Immunology